Deal includes two Phase II compounds from Amylin and additional research candidates from both firms.
Amylin Pharmaceuticals and Takeda Pharmaceutical are joining forces to develop and commercialize therapies for obesity and related indications. Takeda will pay Amylin $75 million up front for a license to its Phase II program with pramlintide/metreleptin and davalintide.
Amylin stands to earn $1 billion in development, commercialization, and sales-based milestones. The agreement also includes additional compounds from both companies’ obesity research programs.
Amylin is responsible for developing each potential molecule through Phase II in the U.S. Takeda will lead development beyond Phase II in the U.S. and all development activities outside the U.S. In most instances, Amylin will be responsible for 20% of development costs associated with obtaining approval for products in the U.S. Takeda will be responsible for 100% of development costs associated with obtaining approval for products outside the U.S.
Takeda will lead product commercialization, both in the U.S. and outside the U.S., and will be responsible for 100% of commercialization costs. Amylin will receive tiered, double-digit royalty payments based on global product sales. Amylin also has the option to co-commercialize the first two approved products in the U.S. and any follow-on products containing the identical active ingredients.
